Management of post-chemotherapy extra-retroperitoneal residual masses Journal Article


Authors: Carver, B. S.; Sheinfeld, J.
Article Title: Management of post-chemotherapy extra-retroperitoneal residual masses
Abstract: Introduction: Testicular cancer is the most common cancer in men age 20-35 years and accounts for approximately 1% of all male malignancies. While the retroperitoneum is often the first and only site of metastatic disease, approximately 40% of patients presenting with metastatic disease will have disease involving extra-retroperitoneal sites. Materials and methods: A medline review was conducted to evaluate peer-reviewed articles reporting on the outcome of patients with germ cell tumors and extra-retroperitoneal metastases. Results: Following chemotherapy, approximately 70% of patients will have residual masses in the retroperitoneum and several series demonstrate that approximately 50% of patients will harbor teratoma or viable GCT in the retroperitoneum. Additionally, up to 35% of patients will have radiographic evidence of extra-retroperitoneal (ERP) masses after chemotherapy. Conclusion: In this manuscript, we will review the current role of surgery for patients with post-chemotherapy residual ERP metastases. © Springer-Verlag 2009.
Keywords: cisplatin; multimodality cancer therapy; combined modality therapy; antineoplastic agent; neoplasm; metastasis; etoposide; antineoplastic combined chemotherapy protocols; pathology; testis tumor; testicular neoplasms; bleomycin; teratoma; surgical resection; testicular cancer; bep protocol; vp p protocol; vp-p protocol; retroperitoneal tumor; neoplasms, germ cell and embryonal; retroperitoneal neoplasms
Journal Title: World Journal of Urology
Volume: 27
Issue: 4
ISSN: 0724-4983
Publisher: Springer  
Date Published: 2009-08-01
Start Page: 489
End Page: 492
Language: English
DOI: 10.1007/s00345-009-0412-2
PUBMED: 19373472
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 3" - "Export Date: 30 November 2010" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Joel Sheinfeld
    254 Sheinfeld
  2. Brett Stewart Carver
    143 Carver